TNFRSF17 and Miyoshi myopathy: While these current US Food and Drug Administration (FDA)-approved CAR T-cells are only indicated for B-cell malignancies, many novel CAR T-cells targeting various antigens are being developed for other cancers, including BCMA for multiple myeloma (MM), EGFRvIII for glioblastoma multiforme (GBM), and MUC1* for breast cancer, among others (2).